These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17545613)

  • 1. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
    Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
    Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
    Ueno S; Tatetsu H; Hata H; Iino T; Niiro H; Akashi K; Tenen DG; Mitsuya H; Okuno Y
    Oncogene; 2009 Nov; 28(46):4116-25. PubMed ID: 19749795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element.
    Bonadies N; Neururer Ch; Steege A; Vallabhapurapu S; Pabst T; Mueller BU
    Oncogene; 2010 Feb; 29(7):1062-72. PubMed ID: 19966852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
    Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
    Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
    Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1.
    Rosenbauer F; Owens BM; Yu L; Tumang JR; Steidl U; Kutok JL; Clayton LK; Wagner K; Scheller M; Iwasaki H; Liu C; Hackanson B; Akashi K; Leutz A; Rothstein TL; Plass C; Tenen DG
    Nat Genet; 2006 Jan; 38(1):27-37. PubMed ID: 16311598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites.
    Lennartsson A; Garwicz D; Lindmark A; Gullberg U
    Gene; 2005 Aug; 356():193-202. PubMed ID: 16019164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
    Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
    J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
    Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
    Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
    Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter.
    Ying H; Chang JF; Parnes JR
    J Immunol; 1998 Mar; 160(5):2287-96. PubMed ID: 9498769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
    Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.
    Nishimura N; Endo S; Ueno S; Ueno N; Tatetsu H; Hirata S; Hata H; Komohara Y; Takeya M; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2017 May; 486(4):916-922. PubMed ID: 28347818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
    Torlakovic E; Malecka A; Myklebust JH; Tierens A; Aasheim HC; Nesland JM; Smeland E; Kvaløy S; Delabie J
    J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
    Chim CS; Pang R; Fung TK; Choi CL; Liang R
    Leukemia; 2007 Dec; 21(12):2527-36. PubMed ID: 17882284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
    Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element.
    Okuno Y; Huang G; Rosenbauer F; Evans EK; Radomska HS; Iwasaki H; Akashi K; Moreau-Gachelin F; Li Y; Zhang P; Göttgens B; Tenen DG
    Mol Cell Biol; 2005 Apr; 25(7):2832-45. PubMed ID: 15767686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b.
    Suzuki M; Yamada T; Kihara-Negishi F; Sakurai T; Hara E; Tenen DG; Hozumi N; Oikawa T
    Oncogene; 2006 Apr; 25(17):2477-88. PubMed ID: 16331260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
    Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
    J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.